Repurposing Licensed Drugs with Activity Against Epstein–Barr Virus for Treatment of Multiple Sclerosis: A Systematic Approach
Vivien Li(The University of Melbourne), Andrew R. Lloyd(Oregon Health & Science University), Corey Smith(QIMR Berghofer Medical Research Institute), Jeannette Lechner‐Scott(John Hunter Hospital), Gavin Giovannoni(Queen Mary University of London), Andrew Potter, William D. Rawlinson(New South Wales Department of Health), Natalia Drosu(Harvard University), David C. Tscharke(Australian National University), Julia M. Morahan, Simon Broadley(Griffith University), Lynne M. Smith(UCLA Medical Center), Suzanne Hodgkinson(UNSW Sydney), Lawrence Steinman(Stanford University), Bruce Taylor(University of London), Rajiv Khanna(QIMR Berghofer Medical Research Institute), Todd A. Hardy(The University of Sydney), Amit Bar‐Or(University of Pennsylvania), Michael Levy(Mass General Brigham), B Frost, Fiona C. McKay(Multiple Sclerosis Foundation), Nigel Caswell
Cited by 14
Related Papers
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
|Neurology|2015|4.6k
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
|New England Journal of Medicine|2016|1.9k
Multiple sclerosis
|Nature Reviews Disease Primers|2018|1.4k